Gauzy Ltd. Announces Board of Directors Changes Following Annual Meeting
Gauzy Ltd. (Nasdaq: GAUZ), a global leader in vision and light control technologies, has announced significant changes to its Board of Directors. Alejandro Weinstein, a longtime investor and former Board member, has been elected to return as Director effective November 1, 2025. Weinstein brings over 30 years of managerial experience, notably as former CEO of CFR Pharmaceuticals S.A., which he led to a multi-billion-dollar sale to Abbott Laboratories.
The Board changes include the departure of two directors: Gal Gitter, whose term as Class I Director expired after 4.5 years of service, and Danny Allouche, who is stepping down after 6.5 years of significant contributions during the company's growth from early venture capital stages through its IPO.
Gauzy Ltd. (Nasdaq: GAUZ), leader mondiale nelle tecnologie per il controllo della luce e della visione, ha annunciato importanti cambiamenti nel suo Consiglio di Amministrazione. Alejandro Weinstein, investitore di lunga data ed ex membro del Consiglio, è stato rieletto come Direttore con effetto dal 1° novembre 2025. Weinstein vanta oltre 30 anni di esperienza manageriale, in particolare come ex CEO di CFR Pharmaceuticals S.A., che ha guidato fino alla vendita multimiliardaria ad Abbott Laboratories.
I cambiamenti nel Consiglio includono l’uscita di due direttori: Gal Gitter, il cui mandato come Direttore di Classe I è terminato dopo 4,5 anni di servizio, e Danny Allouche, che si dimette dopo 6,5 anni di importanti contributi durante la crescita dell’azienda, dal primo stadio di venture capital fino all’IPO.
Gauzy Ltd. (Nasdaq: GAUZ), líder mundial en tecnologías de control de visión y luz, ha anunciado cambios significativos en su Junta Directiva. Alejandro Weinstein, un inversor de larga trayectoria y exmiembro de la Junta, ha sido elegido para regresar como Director con efecto a partir del 1 de noviembre de 2025. Weinstein aporta más de 30 años de experiencia en gestión, destacando su labor como ex CEO de CFR Pharmaceuticals S.A., empresa que lideró hasta su venta multimillonaria a Abbott Laboratories.
Los cambios en la Junta incluyen la salida de dos directores: Gal Gitter, cuyo mandato como Director de Clase I expiró tras 4,5 años de servicio, y Danny Allouche, quien se retira después de 6,5 años de importantes contribuciones durante el crecimiento de la compañía desde sus primeras etapas de capital riesgo hasta su oferta pública inicial.
Gauzy Ltd. (나스닥: GAUZ)는 시각 및 광 제어 기술 분야의 글로벌 선두 기업으로서 이사회의 중대한 변동을 발표했습니다. 오랜 투자자이자 전 이사회 멤버인 Alejandro Weinstein가 2025년 11월 1일부로 이사로 복귀하게 되었습니다. Weinstein은 30년 이상의 경영 경험을 보유하고 있으며, 특히 CFR Pharmaceuticals S.A.의 전 CEO로서 Abbott Laboratories에 수십억 달러 규모로 회사를 매각한 바 있습니다.
이사회 변화에는 두 명의 이사 퇴임이 포함됩니다: 4.5년간 Class I 이사로 재임한 Gal Gitter와, 벤처 초기 단계부터 IPO에 이르기까지 회사 성장에 크게 기여한 Danny Allouche가 6.5년의 임기 후 물러납니다.
Gauzy Ltd. (Nasdaq : GAUZ), leader mondial des technologies de contrôle de la vision et de la lumière, a annoncé d’importants changements au sein de son conseil d’administration. Alejandro Weinstein, investisseur de longue date et ancien membre du conseil, a été réélu en tant que directeur à compter du 1er novembre 2025. Weinstein apporte plus de 30 ans d’expérience managériale, notamment en tant qu’ancien PDG de CFR Pharmaceuticals S.A., qu’il a dirigée jusqu’à une vente de plusieurs milliards de dollars à Abbott Laboratories.
Les changements au conseil incluent le départ de deux administrateurs : Gal Gitter, dont le mandat en tant qu’administrateur de Classe I a expiré après 4,5 ans de service, et Danny Allouche, qui quitte ses fonctions après 6,5 ans de contributions significatives lors de la croissance de l’entreprise, depuis ses débuts en capital-risque jusqu’à son introduction en bourse.
Gauzy Ltd. (Nasdaq: GAUZ), ein weltweit führendes Unternehmen im Bereich Vision- und Lichtsteuerungstechnologien, hat bedeutende Veränderungen in seinem Vorstand bekannt gegeben. Alejandro Weinstein, ein langjähriger Investor und ehemaliges Vorstandsmitglied, wurde mit Wirkung zum 1. November 2025 wieder als Direktor gewählt. Weinstein bringt über 30 Jahre Managementerfahrung mit, insbesondere als ehemaliger CEO von CFR Pharmaceuticals S.A., das er zu einem milliardenschweren Verkauf an Abbott Laboratories führte.
Die Änderungen im Vorstand umfassen den Weggang von zwei Direktoren: Gal Gitter, dessen Amtszeit als Class-I-Direktor nach 4,5 Jahren endete, und Danny Allouche, der nach 6,5 Jahren bedeutender Beiträge während des Unternehmenswachstums von den frühen Venture-Capital-Phasen bis zum Börsengang zurücktritt.
- Addition of Alejandro Weinstein brings valuable experience in global expansion, M&A, and public company leadership
- Board restructuring aims to reduce corporate expenses and maintain operational agility
- New director has proven track record of leading successful public company sale (CFR Pharmaceuticals to Abbott)
- Loss of two experienced board members could temporarily impact institutional knowledge and oversight
Gauzy Pleased to Announce Alejandro Weinstein, Former Director in Gauzy, Elected to Board; A Long-Time Investor and Shareholder Engaged with the Company Since 2016
Gauzy Adopts Leaner Board to Reduce Corporate Expenses and Maintain Agility
TEL AVIV, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader in vision and light control technologies, today announced changes to its Board of Directors following the Company's annual general meeting of shareholders. The shareholders of the Company have elected longtime company investor and former Board member Alejandro Weinstein, to return to the Board as a Director with his term commencing November 1, 2025.
Alejandro Weinstein brings over 30 years of managerial experience in global companies. He previously served as CEO of CFR Pharmaceuticals S.A., where he transformed the business into a publicly listed global pharmaceutical enterprise that ultimately sold to Abbott Laboratories in a multi-billion-dollar transaction. His extensive experience in global expansion, M&A, and public company leadership will be instrumental as Gauzy scales its operations and advances its position as a leader in vision and light control technologies.
“We are excited to welcome Alejandro back to our Board,” said Eyal Peso, CEO and Chairman of Gauzy. “Alejandro brings invaluable experience as a CEO who successfully built a global leader in the pharmaceutical industry that went public under his leadership. His deep expertise in international growth, public company governance, and private equity will be instrumental as we continue to scale Gauzy’s global presence and deliver long-term value to our shareholders.”
Mr. Weinstein commented, “I am honored to be elected and returning to Gauzy's Board. As a longtime supporter of Gauzy, I continue to be inspired by its rapid expansion in the light and vision control market. I look forward to being an integral part in its future growth and creating long-term value for our shareholders.”
Gal Gitter concluded his service on the Board following the expiration of his term as a Class I Director. Mr. Peso shared, “On behalf of Gauzy, I would like to thank Gal for his service over the past four and a half years and valuable contributions.”
In addition, long-time Director and Board member, Danny Allouche is stepping down from the Board. “We would also like to extend a special thanks and deep appreciation to Danny for his dedicated service and significant contributions to Gauzy during some of our most formative years,” said Mr. Peso. “We wish him all the best in his future endeavours.”
Mr. Peso added, “During his six and a half years of service, Danny has been instrumental in helping Gauzy grow from its early days of venture capital fundraising through strategic M&A accomplishments during our private company phase, and most recently as a strong supporter of our IPO. His leadership brought immense value to the Board and played a key role in shaping Gauzy’s long-term strategy.”
Mr. Allouche added, “It has been an honor serving on Gauzy's Board of Directors for the last six and half years, and seeing its tremendous growth over the years. Having witnessed Gauzy's commitment to growth and innovation, I am confident that the company will continue to deliver on its goals, and I look forward to following Gauzy's future success. Thank you for this opportunity to serve, and be a part of Gauzy's achievements to date.”
About Gauzy
Gauzy Ltd. is a fully-integrated light and vision control company, focused on the research, development, manufacturing, and marketing of vision and light control technologies that are developed to support safe, sustainable, comfortable, and agile user experiences across various industries. Headquartered in Tel Aviv, Israel, the company has additional subsidiaries and entities based in Germany, France, the United States, Canada, China, Singapore, and the United Arab Emirates. Gauzy serves leading brands across aeronautics, automotive, and architecture in over 60 countries through direct fulfillment and a certified and trained distribution channel.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Gauzy’s strategic and business plans, technology, relationships, objectives and expectations for its business, growth, the impact of trends on and interest in its business, intellectual property, products and its future results, operations and financial performance and condition and may be identified by the use of words such as “may,” “seek,” “will,” “consider,” “likely,” “assume,” “estimate,” “expect,” “anticipate,” “intend,” “believe,” “do not believe,” “aim,” “predict,” “plan,” “project,” “continue,” “potential,” “guidance,” “objective,” “outlook,” “trends,” “future,” “could,” “would,” “should,” “target,” “on track” or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements reflect Gauzy’s current views, plans, or expectations with respect to future events and financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Gauzy’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict including, without limitation, the following: Gauzy invests significant effort and capital seeking validation of its light and vision control products with OEMs and Tier 1 suppliers, mainly in the aeronautics and automobile markets, and there can be no assurance that it will win production models, which could adversely affect its future business, results of operations and financial condition; failure to make competitive technological advances will put Gauzy at a disadvantage and may lead to a negative operational and financial outcome; Gauzy being an early growth-stage company with a history of losses and its anticipation that it expects to continue to incur significant losses for the foreseeable future; its operating results and financial condition have fluctuated in the past and may fluctuate in the future; it is exposed to high repair and replacement costs; it may not be able to accurately estimate the future supply and demand for its light and vision control products, which could result in a variety of inefficiencies in its business and hinder its ability to generate revenue; if it fails to accurately predict its manufacturing requirements, it could incur additional costs or experience delays; the estimates and forecasts of market opportunity and market growth it provides may prove to be inaccurate, and it cannot assure that its business will grow at similar rates, or at all; it may be unable to adequately control the capital expenditures and costs associated with its business and operations; it may need to raise additional capital before it can expect to become profitable from sales of its light and vision control products, which such additional capital may not be available on acceptable terms, or at all, and failure to obtain this necessary capital when needed may force it to delay, limit or terminate its product development efforts or other operations; shortages in supply, price increases or deviations in the quality of the raw materials used to manufacture its products could adversely affect its sales and operating results; its business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by the ongoing conflict between Russia and Ukraine; it is subject to, and must remain in compliance with, numerous laws and governmental regulations across various countries concerning the manufacturing, use, distribution and sale of its light and vision control products, and some of its customers also require that it complies with other unique requirements relating to these matters; if it is unable to obtain, maintain and protect effective intellectual property rights for its products throughout the world, it may not be able to compete effectively in the markets in which it operates; the market price of its ordinary shares may be volatile or may decline steeply or suddenly regardless of its operating performance, and it may not be able to meet investor or analyst expectations; its indebtedness could adversely affect its ability to raise additional capital to fund operations, limit its ability to react to changes in the economy or its industry and prevent it from meeting its financial obligations; it has limited operating experience as a publicly traded company in the United States; conditions in Israel could materially and adversely affect its business; and any other risks and uncertainties, including, but not limited to, the risks and uncertainties in the Company’s reports filed from time to time with the SEC, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the SEC on March 11, 2025. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Gauzy or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Gauzy undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.
Contacts
Media:
Brittany Kleiman Swisa
Gauzy Ltd.
press@gauzy.com
Investors:
Dan Scott, ICR Inc.
ir@gauzy.com
FAQ
Who is joining Gauzy's (GAUZ) Board of Directors in 2025?
Which board members are leaving Gauzy (GAUZ) in 2025?
What is Alejandro Weinstein's background before joining Gauzy's board?
Why is Gauzy (GAUZ) restructuring its board of directors?
